Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Vaccines01:30

Cancer Vaccines

936
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
936
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

469
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
469

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Updates on the Perioperative Management of Resectable Non-Small Cell Lung Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

The Impact of Neoadjuvant Chemoradiation Therapy on Non-Tumorous Barrett's Dysplasia of the Esophagus: A Multicenter Cohort Study.

Journal of clinical medicine·2026
Same author

Stereotactic Body Radiation Therapy Utilization Trends for Stage I Non-Small Cell Lung Cancer.

Chest·2025
Same author

A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK -positive Non-small Cell Lung Cancer in the United States.

American journal of clinical oncology·2025
Same author

CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLC.

JTO clinical and research reports·2025
Same author

A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2025
Same journal

Pleuropulmonary Infectious Diseases: Impact of the Diseases and the Scarce Literature.

Thoracic surgery clinics·2026
Same journal

TB or Not TB-Septic or Resect? That Is the Question.

Thoracic surgery clinics·2026
Same journal

Surgery for Pulmonary Aspergillosis.

Thoracic surgery clinics·2026
Same journal

Current Treatment for Mediastinitis.

Thoracic surgery clinics·2026
Same journal

Surgical Management of Pulmonary Mucormycosis.

Thoracic surgery clinics·2026
Same journal

Surgical Management of Pulmonary Hydatid Disease.

Thoracic surgery clinics·2026
See all related articles

Related Experiment Video

Updated: Jan 10, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K

Neoadjuvant Immunotherapy.

Jay M Lee1

  • 1Thoracic Oncology Program, Jonsson Comprehensive Cancer Center; Division of Thoracic Surgery, David Geffen School of Medicine, UCLA Health, Los Angeles, CA, USA.

Thoracic Surgery Clinics
|November 19, 2025
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitor (ICI) monotherapy is investigational for early-stage non-small cell lung cancer. Combination chemotherapy and ICI (CT-ICI) demonstrates superior pathologic outcomes, becoming a preferred strategy.

Keywords:
Early stageImmune checkpoint inhibitionImmunotherapyLung cancerNeoadjuvantNon-small cell lung carcinomaPerioperativeResectable

More Related Videos

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

10.7K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

23.9K

Related Experiment Videos

Last Updated: Jan 10, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K
Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

10.7K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

23.9K

Area of Science:

  • Oncology
  • Immunotherapy
  • Thoracic Surgery

Background:

  • Immune checkpoint inhibitor (ICI) monotherapy is currently investigational for early-stage non-small cell lung cancer (eNSCLC).
  • Neoadjuvant trials identified key early response markers like major pathologic regression and pathologic complete response (pCR).

Purpose of the Study:

  • To evaluate the efficacy and safety of neoadjuvant immune checkpoint inhibitors (ICIs) in eNSCLC.
  • To compare ICI monotherapy with combination chemotherapy and ICI (CT-ICI).

Main Methods:

  • Analysis of Phase 2 neoadjuvant trials for ICI monotherapy and CT-ICI.
  • Evaluation of early response markers including major pathologic regression, pCR, and objective response rate.
  • Consideration of long-term outcomes required for regulatory approval.

Main Results:

  • CT-ICI demonstrated superior pathologic outcomes compared to ICI monotherapy.
  • pCR is a valuable early efficacy marker, but long-term survival data are crucial for FDA approval.
  • ICI monotherapy showed a favorable safety and tolerability profile.
  • Chemotherapy-free dual ICI regimens are still under investigation.

Conclusions:

  • Combination CT-ICI is the preferred neoadjuvant strategy for eNSCLC based on superior pathologic outcomes.
  • While early response markers are informative, definitive FDA approval hinges on long-term event-free or overall survival.
  • Further research is needed for chemotherapy-free dual ICI regimens in eNSCLC.